XML 29 R17.htm IDEA: XBRL DOCUMENT
v3.25.1

DERIVATIVE INSTRUMETNS AND FAIR VALUE MEASUREMENTS (Notes) | 3 Months Ended
--- | ---
Mar. 29, 2025
Derivative Instruments and Fair Value Measurements [Abstract] |
Derivative Instruments and Fair Value Measurements | DERIVATIVE INSTRUMENTS AND FAIR VALUE The Company is exposed to certain market risks such as changes in interest rates, foreign currency exchange rates, and commodity prices, which exist as a part of its ongoing business operations. Management uses derivative and nonderivative financial and commodity instruments, including futures, options, and swaps, where appropriate, to manage these risks. Instruments used as hedges must be effective at reducing the risk associated with the exposure being hedged. The Company designates derivatives and nonderivative hedging instruments as cash flow hedges, fair value hedges, net investment hedges, and uses other contracts to reduce volatility in interest rates, foreign currency and commodities. As a matter of policy, the Company does not engage in trading or speculative hedging transactions. Derivative instruments are classified on the Consolidated Balance Sheet based on the contractual maturity of the instrument or the timing of the underlying cash flows of the instrument for derivatives with contractual maturities beyond one year. Any collateral associated with derivative instruments is classified as other assets or other current liabilities on the Consolidated Balance Sheet depending on whether the counterparty collateral is in an asset or liability position. Margin deposits related to exchange-traded commodities are recorded in accounts receivable, net on the Consolidated Balance Sheet. On the Consolidated Statement of Cash Flows, cash flows associated with derivative instruments are classified according to the nature of the underlying hedged item. Cash flows associated with collateral and margin deposits on exchange-traded commodities are classified as investing cash flows when the collateral account is in an asset position and as financing cash flows when the collateral account is in a liability position. Total notional amounts of the Company’s derivative instruments as of March 29, 2025 and December 28, 2024 were as follows:
(millions) | March 29, 2025 | December 28, 2024
Foreign currency exchange contracts | $ | 3,569 |  | $ | 3,243 |
Cross-currency contracts | 2,030 |  | 2,030 |
Interest rate contracts | 1,050 |  | 1,050 |
Commodity contracts | 196 |  | 285 |
Total | $ | 6,845 |  | $ | 6,608 |
Following is a description of each category in the fair value hierarchy and the financial assets and liabilities of the Company that were included in each category at March 29, 2025 and December 28, 2024, measured on a recurring basis. Level 1 – Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market. For the Company, Level 1 financial assets and liabilities consist primarily of commodity derivative contracts. Level 2 – Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. For the Company, Level 2 financial assets and liabilities consist of interest rate swaps, cross-currency swaps and over-the-counter commodity and currency contracts. The Company’s calculation of the fair value of interest rate swaps is derived from a discounted cash flow analysis based on the terms of the contract and the interest rate curve. Foreign currency contracts are valued using an income approach based on forward rates less the contract rate multiplied by the notional amount. Cross-currency contracts are valued based on changes in the spot rate at the time of valuation compared to the spot rate at the time of execution, as well as the change in the interest differential between the two currencies. The Company’s calculation of the fair value of level 2 financial assets and liabilities takes into consideration the risk of nonperformance, including counterparty credit risk. Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset or liability. The Company did not have any Level 3 financial assets or liabilities as of March 29, 2025 or December 28, 2024. The following table presents assets and liabilities that were measured at fair value in the Consolidated Balance Sheet on a recurring basis as of March 29, 2025 and December 28, 2024: Derivatives designated as hedging instruments
| March 29, 2025 |  | December 28, 2024
(millions) | Level 1 | Level 2 | Total |  | Level 1 | Level 2 | Total
Assets: |  |  |  |  |  |  |
Cross-currency contracts: |  |  |  |  |  |  |
Other current assets | $ | — |  | $ | 14 |  | $ | 14 |  |  | $ | — |  | $ | 47 |  | $ | 47 |
Other assets | — |  | 15 |  | 15 |  |  | — |  | 51 |  | 51 |
Total assets | $ | — |  | $ | 29 |  | $ | 29 |  |  | $ | — |  | $ | 98 |  | $ | 98 |
Liabilities: |  |  |  |  |  |  |
Cross-currency contracts: |  |  |  |  |  |  |
Other current liabilities | $ | — |  | $ | (13) |  | $ | (13) |  |  | $ | — |  | $ | (2) |  | $ | (2) |
Other liabilities | — |  | (2) |  | (2) |  |  | — |  | (9) |  | (9) |
Interest rate contracts(a): |  |  |  |  |  |  |
Other current liabilities | — |  | — |  | — |  |  | — |  | — |  | — |
Other liabilities | — |  | (32) |  | (32) |  |  | — |  | (41) |  | (41) |
Total liabilities | $ | — |  | $ | (47) |  | $ | (47) |  |  | $ | — |  | $ | (52) |  | $ | (52) |
(a) The fair value of the related hedged portion of the Company's long-term debt, a Level 2 liability, was $0.4 billion as of March 29, 2025 and December 28, 2024. Derivatives not designated as hedging instruments
| March 29, 2025 |  | December 28, 2024
(millions) | Level 1 | Level 2 | Total |  | Level 1 | Level 2 | Total
Assets: |  |  |  |  |  |  |
Foreign currency exchange contracts: |  |  |  |  |  |  |
Other current assets | $ | — |  | $ | 54 |  | $ | 54 |  |  | $ | — |  | $ | 65 |  | $ | 65 |
Other assets | — |  | 4 |  | 4 |  |  | — |  | 2 |  | 2 |
Interest rate contracts: |  |  |  |  |  |  |
Other current assets | — |  | 6 |  | 6 |  |  | — |  | 6 |  | 6 |
Other assets | — |  | — |  | — |  |  | — |  | 1 |  | 1 |
Commodity contracts: |  |  |  |  |  |  |
Other current assets | 7 |  | — |  | 7 |  |  | 4 |  | — |  | 4 |
Total assets | $ | 7 |  | $ | 64 |  | $ | 71 |  |  | $ | 4 |  | $ | 74 |  | $ | 78 |
Liabilities: |  |  |  |  |  |  |
Foreign currency exchange contracts: |  |  |  |  |  |  |
Other current liabilities | $ | — |  | $ | (24) |  | $ | (24) |  |  | $ | — |  | $ | (33) |  | $ | (33) |
Other liabilities | — |  | (3) |  | (3) |  |  | — |  | (1) |  | (1) |
Interest rate contracts: |  |  |  |  |  |  |
Other current liabilities | — |  | (8) |  | (8) |  |  | — |  | (8) |  | (8) |
Other liabilities | — |  | — |  | — |  |  | — |  | (1) |  | (1) |
Commodity contracts: |  |  |  |  |  |  |
Other current liabilities | (1) |  | — |  | (1) |  |  | (7) |  | — |  | (7) |
Total liabilities | $ | (1) |  | $ | (35) |  | $ | (36) |  |  | $ | (7) |  | $ | (43) |  | $ | (50) |
The Company has designated its outstanding foreign currency denominated debt as a net investment hedge of a portion of the Company’s investment in its subsidiaries’ foreign currency denominated net assets. The carrying value of this debt, including current and long-term, was approximately $0.6 billion and $1.2 billion as of March 29, 2025 and December 28, 2024, respectively. The following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for existing fair value hedges as of March 29, 2025 and December 28, 2024.
(millions) |  | Line Item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying amount of the hedged liabilities |  | Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged liabilities (a)
|  |  |  | March 29, 2025 | December 28, 2024 |  | March 29, 2025 | December 28, 2024
Interest rate contracts |  | Current maturities of long-term debt |  | $ | — |  | $ | 627 |  |  | $ | — |  | $ | 1 |
Interest rate contracts |  | Long-term debt |  | $ | 1,014 |  | $ | 1,005 |  |  | $ | (34) |  | $ | (43) |
(a) The fair value adjustment related to current maturities of long-term debt includes $1 million from discontinued hedging relationships as of December 28, 2024. The fair value adjustment related to long-term debt includes $(1) million from discontinued hedging relationships as of March 29, 2025 and December 28, 2024, respectively. The Company has elected to not offset the fair values of derivative assets and liabilities executed with the same counterparty that are generally subject to enforceable netting agreements. However, if the Company were to offset and record the asset and liability balances of derivatives on a net basis, the amounts presented in the Consolidated Balance Sheet as of March 29, 2025 and December 28, 2024 would be adjusted as detailed in the following table:
As of March 29, 2025: |  | Gross Amounts Not Offset in the Consolidated Balance Sheet |
| Amounts Presented in the Consolidated Balance Sheet | Financial Instruments | Cash Collateral Received/ Posted | Net Amount
Total asset derivatives | $ | 100 |  | $ | (61) |  | $ | 39 |  | $ | 78 |
Total liability derivatives | $ | (83) |  | $ | 61 |  | $ | 22 |  | $ | — |
As of December 28, 2024: |  | Gross Amounts Not Offset in the Consolidated Balance Sheet |
| Amounts Presented in the Consolidated Balance Sheet | Financial Instruments | Cash Collateral Received/ Posted | Net Amount
Total asset derivatives | $ | 176 |  | $ | (88) |  | $ | 61 |  | $ | 149 |
Total liability derivatives | $ | (102) |  | $ | 88 |  | $ | 14 |  | $ | — |
During the quarter ended March 30, 2024, the Company settled certain cross currency swaps resulting in a net realized loss of approximately $7 million. These cross currency swaps were accounted for as net investment hedges and the related net gain (loss) was recorded in accumulated other comprehensive income. The effect of derivative instruments on the Consolidated Statements of Income and Comprehensive Income for the quarters ended March 29, 2025 and March 30, 2024 was as follows: Derivatives and non-derivatives in net investment hedging relationships
(millions) | Gain (loss) recognized in AOCI |  | Gain (loss) excluded from assessment of hedge effectiveness | Location of gain (loss) in income of excluded component
| March 29, 2025 |  | March 30, 2024 |  | March 29, 2025 |  | March 30, 2024 |
Foreign currency denominated long-term debt | $ | (24) |  |  | $ | 37 |  |  | $ | — |  |  | $ | — |  |
Cross-currency contracts | (73) |  |  | 34 |  |  | 11 |  |  | 8 |  | Interest expense
Total | $ | (97) |  |  | $ | 71 |  |  | $ | 11 |  |  | $ | 8 |  |
Derivatives not designated as hedging instruments
(millions) | Location of gain (loss) recognized in income | Gain (loss) recognized in income
|  | March 29, 2025 |  | March 30, 2024
Foreign currency exchange contracts | COGS | $ | (17) |  |  | $ | (1) |
Foreign currency exchange contracts | Other income (expense), net | 6 |  |  | 4 |
Foreign currency exchange contracts | SG&A | 13 |  |  | 9 |
Interest rate contracts | Interest expense | 1 |  |  | — |
Commodity contracts | COGS | 14 |  |  | (17) |
Total |  | $ | 17 |  |  | $ | (5) |
The effect of fair value and cash flow hedge accounting on the Consolidated Income Statement for the quarters ended March 29, 2025 and March 30, 2024:
|  |  |  |  |  | March 29, 2025 |  |  |  | March 30, 2024
(millions) |  |  |  | Interest Expense |  |  |  | Interest Expense
Total amounts of income and expense line items presented in the Consolidated Income Statement in which the effects of fair value or cash flow hedges are recorded |  |  |  | $ | 63 |  |  |  |  | $ | 83 |
| Gain (loss) on fair value hedging relationships: |  |  |  |  |  |  |  |
| Interest contracts: |  |  |  |  |  |  |  |
| Hedged items |  |  |  | (8) |  |  |  |  | 1 |
| Derivatives designated as hedging instruments |  |  |  | 8 |  |  |  |  | 1 |
| Gain (loss) on cash flow hedging relationships: |  |  |  |  |  |  |  |
| Interest contracts: |  |  |  |  |  |  |  |
| Amount of gain (loss) reclassified from AOCI into income |  |  |  | 1 |  |  |  |  | (2) |
During the next 12 months, the Company expects $8 million of net deferred gains reported in AOCI at March 29, 2025 to be reclassified to income, assuming market rates remain constant through contract maturities. Certain of the Company’s derivative instruments contain provisions requiring the Company to post collateral on those derivative instruments that are in a liability position when the value exceeds certain thresholds with each counterparty. In addition, certain derivative instruments contain provisions that would be triggered in the event the Company defaults on its debt agreements. The collateral posting requirements as of March 29, 2025, triggered by threshold contingent features was not material. Other fair value measurements Fair value measurements on a nonrecurring basis During the quarter ended March 30, 2024, the Company announced the reconfiguration of the North America frozen supply chain network and the reconfiguration of the European cereal supply chain network. The North America frozen supply chain actions have since been fully implemented, while the European cereal supply chain program remains in process. As part of these programs, the Company is consolidating the usage of and disposing certain long-lived assets, including manufacturing facilities. See Note 4 for more information regarding these restructuring programs. During the quarter ended March 30, 2024, long-lived assets of $62 million related to a frozen foods manufacturing facility in the Company's North America reportable segment, were written down to an estimated fair value of approximately $41 million resulting in an impairment charge of $21 million recorded in COGS. During the quarter ended March 30, 2024, long-lived assets of $99 million related to a cereal manufacturing facility in the Company's Europe reportable segment, were written down to an estimated fair value of $60 million resulting in an impairment charge of $39 million recorded in COGS. The Company's calculation of the fair value of these long-lived assets is based on Level 3 inputs, including market comparables, market trends and the condition of the assets. Marketable securities During the first quarter of 2024, the Company amended the U.S. retiree health and welfare plan to create a sub-trust to permit the payment of certain benefits for active union employees using a surplus totaling $175 million from the retiree plan. During the quarter ended March 30, 2024, the Company invested the $175 million in a short-term investment fund that primarily holds short-term debt instruments. The marketable securities portfolio is designated to be used to pay for active union employee benefits. During the quarter ended March 29, 2025, the Company recorded gross sales of marketable securities of approximately $84 million and gross purchases of marketable securities of approximately $72 million. The portfolio's fair value was approximately $129 million as of March 29, 2025. The classification of these marketable securities as current or noncurrent depends on our intended holding period and the securities are measured at Level 1 quoted market prices. Equity investments We hold equity investments in certain companies that we do not have the ability to exercise significant influence. Equity investments without a readily determinable fair value are recorded at original cost. Investments with a readily determinable fair value, which are Level 2 investments, are measured at fair value based on observable market price changes, with gains and losses recorded through net earnings. Equity investments were approximately $40 million as of March 29, 2025 and December 28, 2024. Additionally, these investments were recorded within Other assets on the Consolidated Balance Sheet. Financial instruments The carrying values of the Company’s short-term items, including cash, cash equivalents, accounts receivable, accounts payable, notes payable and current maturities of long-term debt approximate fair value. The fair value of the Company’s long-term debt, which are Level 2 liabilities, is calculated based on broker quotes. The fair value and carrying value of the Company's long-term debt was $5.0 billion as of March 29, 2025. The fair value and carrying value of the Company's long-term debt was $4.9 billion and $5.0 billion, respectively, as of December 28, 2024. Counterparty credit risk concentration and collateral requirements The Company is exposed to credit loss in the event of nonperformance by counterparties on derivative financial and commodity contracts. Management believes a concentration of credit risk with respect to derivative counterparties is limited due to the credit ratings and use of master netting and reciprocal collateralization agreements with the counterparties and the use of exchange-traded commodity contracts. Master netting agreements apply in situations where the Company executes multiple contracts with the same counterparty. Certain counterparties represent a concentration of credit risk to the Company. If those counterparties fail to perform according to the terms of derivative contracts, this would result in a loss to the Company, net of collateral already received from those counterparties. As of March 29, 2025, the concentration of credit risk to the Company was immaterial. For certain derivative contracts, reciprocal collateralization agreements with counterparties call for the posting of collateral in the form of cash, treasury securities or letters of credit if a fair value loss position to the Company or its counterparties exceeds a certain amount. In addition, the Company is required to maintain cash margin accounts in connection with its open positions for exchange-traded commodity derivative instruments executed with the counterparty that are subject to enforceable netting agreements. As of March 29, 2025, the Company posted $57 million related to reciprocal collateralization agreements. As of March 29, 2025, the Company posted $4 million in margin deposits for exchange-traded commodity derivative instruments, which was reflected as an increase in accounts receivable, net on the Consolidated Balance Sheet. Management believes concentrations of credit risk with respect to accounts receivable is limited due to the generally high credit quality of the Company’s major customers, as well as the large number and geographic dispersion of smaller customers.

X
- Definition Derivative instruments and fair value measurements + References No definition available. + Details
Name: | k_DerivativeInstrumentsAndFairValueMeasurementsAbstract
Namespace Prefix: | k_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for derivatives and fair value of assets and liabilities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details
Name: | us-gaap_DerivativesAndFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration